Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Eiseman

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 ratsK P Stecklair, D R Hamburger, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in miceB A Conley, T S Ramsland, D L Sentz, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2000
Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase IE M Sharkey, H B O'Neill, M J Kavarana, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemanniiM J Egorin, D L Sentz, D M Rosen, et al.
Cancer Research|November 11, 1998
Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancerJ L Eiseman, F A Rogers, Y Guo, et al.
Cancer Chemotherapy and Pharmacology|December 8, 2004
Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumorsT S Garimella, D D Ross, J L Eiseman, et al.
Cancer Research|August 17, 2000
Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esteraseC L Morton, M Wierdl, L Oliver, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 miceJ L Eiseman, N D Eddington, J Leslie, et al.
Journal of Medicinal Chemistry|January 5, 1996
Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecaneY Li, J L Eiseman, D L Sentz, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trialJ S Abrams, J L Eiseman, T J Melink, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 ratsK P Stecklair, D R Hamburger, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in miceB A Conley, T S Ramsland, D L Sentz, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2000
Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase IE M Sharkey, H B O'Neill, M J Kavarana, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemanniiM J Egorin, D L Sentz, D M Rosen, et al.
Cancer Research|November 11, 1998
Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancerJ L Eiseman, F A Rogers, Y Guo, et al.
Cancer Chemotherapy and Pharmacology|December 8, 2004
Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumorsT S Garimella, D D Ross, J L Eiseman, et al.
Cancer Research|August 17, 2000
Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esteraseC L Morton, M Wierdl, L Oliver, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 miceJ L Eiseman, N D Eddington, J Leslie, et al.
Journal of Medicinal Chemistry|January 5, 1996
Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecaneY Li, J L Eiseman, D L Sentz, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trialJ S Abrams, J L Eiseman, T J Melink, et al.
Pageof 4